Physician profile
Meghan Pollard
NPI 1790338531
$3,221.34
in general payments reported to CMS, 2019-2025
22 companies · $359 in 2025
The $359 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $982 · 2022: $422 · 2023: $521 · 2024: $936 · 2025: $359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,816.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,816.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $394.53 | 2021 | |
| Alexion Pharmaceuticals, INC. | $353.34 | 2023-2024 | Ultomiris |
| Amgen INC. | $343.70 | 2023-2025 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $277.30 | 2022-2025 | Mounjaro, Zepbound |
| Biohaven Pharmaceutical Holding Company LTD. | $253.84 | 2022 | |
| Abbvie INC. | $239.81 | 2021-2024 | |
| Novo Nordisk INC | $196.58 | 2021-2024 | Ozempic, Rybelsus |
| Inspire Medical Systems, INC. | $171.38 | 2024 | Inspire |
| Eisai INC. | $155.64 | 2021-2025 | |
| Biogen, INC. | $135.53 | 2021 | |
| Astellas Pharma US INC | $125.00 | 2023 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $125.00 | 2024 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.56 | 2024 | Jardiance |
| Mylan Specialty L.P. | $96.82 | 2022 | |
| Gilead Sciences, INC. | $60.07 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $54.71 | 2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.94 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $22.01 | 2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $19.37 | 2022 | |
| Dexcom, INC. | $17.75 | 2024 | Dexcom G6 Transmitter |
| Antares Pharma, INC. | $15.09 | 2025 | Xyosted |
| Pfizer INC. | $13.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meghan Pollard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.